Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Successfully navigate the complex worlds of compliance, legislation, policy regulation, and industry developments with the expertise of our worldwide network of expert analysts and journalists.
Our team of global contributors helps you to anticipate challenges, minimize risks and maximize opportunities. Pink Sheet is the biopharma industry’s go-to source for business-critical insights and policy and regulatory intelligence.
How it helps
Pink Sheet gives you the power to go behind the regulatory and compliance headlines to understand the implications of worldwide industry developments on your business.
How it works
With a network of journalists and analysts crisscrossing the globe, our industry experts and thought leaders track product progress from submission to approval. We also draw on the strength and expertise of the rest of the Pharma Intelligence family of analytical and market intelligence tools.
Analysis and opinion covers key topic areas such as:
Pink Sheet
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
Topic US Election 2020 Drug Pricing
Pink Sheet
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Topic US Election 2020 Drug Pricing
Pink Sheet
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Topic US Election 2020 Drug Pricing
Pink Sheet
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Topic US Election 2020 FDA
Pink Sheet
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.
Topic EU Biosimilars
Pink Sheet
CBER director said that all the manufacturing data may not be available, but the safety and efficacy data needed for a BLA are expected before an emergency use authorization is granted.
Topic Coronavirus Vaccines
Pink Sheet
Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.
Topic US Election 2020 Coronavirus
Pink Sheet
Joe Biden’s presidential campaign now has a plan to address supply chains and encourage US-based manufacturing of prescription drugs. That affirms the unlikely national prominence of the issue – and reduces the chances of meaningful legislation this year.
Pink Sheet
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
Pink Sheet
It is easy to see why Sen. Bernie Sanders would be the least popular pick for biopharma executives among the contenders in the Presidential race. But for industry lobbyists, it might not be the worst outcome – at least in terms of clarifying positions.
Topic US Election 2020
Pink Sheet
Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House.
Pink Sheet
The US pharmaceutical industry has to be pleased with the tone set by the Democratic National Convention that formally nominated Joe Biden for President. The campaign looks to be about Trump, COVID, and healing racial divisions, not drug prices
Topic US Election 2020
Pink Sheet
US FDA Commissioner Hahn’s credibility is in question following an emergency use authorization for convalescent plasma, leading some former officials to push for new agency leadership. Hahn’s actions, combined with President Trump’s attack on FDA staff as being ‘deep state’ actors, may compromise the public trust in the agency’s work during COVID-19 and beyond, former FDA officials say
Pink Sheet
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Topic US Election 2020
In Vivo, Medtech Insight, Pink Sheet, Scrip
Explore how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.
Topic Coronavirus
Pink Sheet
28 Sep 2020
Pink Sheet
28 Sep 2020
Pink Sheet
28 Sep 2020
Pink Sheet
27 Sep 2020
Pink Sheet
27 Sep 2020
Pink Sheet
27 Sep 2020
Pink Sheet
27 Sep 2020
Pink Sheet
27 Sep 2020
Pink Sheet
27 Sep 2020
Pink Sheet
25 Sep 2020
Pink Sheet
25 Sep 2020
Pink Sheet
24 Sep 2020
Pink Sheet
24 Sep 2020
Pink Sheet
24 Sep 2020
Pink Sheet
24 Sep 2020
New York, USA
Brenda specializes in
+39 year(s) experience
Washington DC, USA
Cathy specializes in
+39 year(s) experience
Washington DC, USA
Denise specializes in
+38 year(s) experience
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date